Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TOP2A | P11388 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5908705 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1TOP2BLMNATOP2A | |
| SCHEMBL5908447 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1TOP2BLMNATOP2A | |
| SCHEMBL262200 | 0.83 | MEN1 (0.48) | KDM4EALDH1A1TOP2BLMNATOP2A | |
| SCHEMBL262201 | 0.83 | MEN1 (0.48) | KDM4EALDH1A1TOP2BLMNATOP2A | |
| SCHEMBL29576548 | 0.81 | ALDH1A1 (0.43) | KDM4EALDH1A1TOP2BLMNATOP2A | |
| SCHEMBL5908567 | 0.81 | ALDH1A1 (0.43) | KDM4EALDH1A1TOP2BLMNATOP2A | |
| SCHEMBL501238 | 0.78 | KDM4E (0.69) | KDM4EALDH1A1TOP2BLMNATOP2A | |
| SCHEMBL29442121 | 0.78 | KDM4E (0.69) | KDM4EALDH1A1TOP2BLMNATOP2A | |
| SCHEMBL5908463 | 0.76 | KDM4E (0.35) | KDM4EALDH1A1TOP2BLMNATOP2A | |
| SCHEMBL5908450 | 0.76 | KDM4E (0.35) | KDM4EALDH1A1TOP2BLMNATOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056917-B2 | Drug efflux pump inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-06-06 | — | — | US | disclosed |
| US-20060106034-A1 | Drug efflux pump inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | TRINE PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| EP-1389463-A1 | MEDICINE FOR INHIBITING DRUG ELIMINATION PUMP | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| US-20030092720-A1 | Drug efflux pump inhibitor | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092720-A1 | Drug efflux pump inhibitor | ABCB11, ABCB1, ABCC1 | KDM4E 2648/4885ALDH1A1 1515/4885TOP2B 3286/4885 |
| US-20060106034-A1 | Drug efflux pump inhibitor | ABCB11, ABCB1, ABCC5 | KDM4E 2673/4885ALDH1A1 1244/4885TOP2B 3814/4885 |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | ABCB11, ATP6AP1, HRH2 | KDM4E 1928/4885ALDH1A1 1997/4885TOP2B 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.